Genitourinary Cancer. When Prostate Brachytherapy Fails: A Case Report and Discussion. The Oncologist 2005;10:

Size: px
Start display at page:

Download "Genitourinary Cancer. When Prostate Brachytherapy Fails: A Case Report and Discussion. The Oncologist 2005;10:"

Transcription

1 This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Genitourinary Cancer When Prostate Brachytherapy Fails: A Case Report and Discussion Cigall Kadoch, a Anthony V. D Amico, b Richard H. Matthews c a University of California, Berkeley, California, USA, and Harvard Medical School, Boston, Massachusetts, USA; b Department of Radiation Oncology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA; c Department of Radiation Oncology, Beth Israel/Deaconess Medical Center, Harvard Medical School, and Boston Veterans Health Affairs Medical Centers, Boston, Massachusetts, USA Key Words. Prostate cancer Brachytherapy Prostate-specific antigen failure Local recurrence Abstract For appropriately selected brachytherapy patients, prostate-specific antigen failure is uncommon. Our patient experienced biochemical failure after 125 I brachytherapy treatment for low-risk prostate adenocarcinoma. We suggest neoadjuvant/ adjuvant hormonal therapy combined with pelvic external-beam radiation therapy as a reasonable salvage treatment. At the 2-year follow-up, he is apparently doing well. With limited data available, salvage management for this situation is presently investigational. The Oncologist 2005;10: Introduction Prostate cancer affects more than 180,000 men each year and is the second-leading cause of cancer death in men. Approximately 85% of all cases diagnosed yearly in the modern prostate-specific antigen (PSA) era present as clinically localized prostate cancer, treated with curative intent by means of external-beam radiation therapy (XRT), brachytherapy, or radical prostatectomy. Transperineal ultrasound-guided prostate brachytherapy is a viable option in the management of early stage cancer of the prostate gland, targeting high radiation doses to the prostate alone or, in some techniques, the prostate and adjacent portion of the seminal vesicles. Prostate low-dose rate 125 I brachytherapy, first reported by Grimm et al. [1], used to treat probable organ-confined disease has been a treatment of choice; the concept of delivering a high dose to the prostate itself with rapid dose fall-off in surrounding normal tissues should presumably diminish complications. Beyer [2] has suggested that this is the case with significant complications occurring in <5% of a cohort of 734 prostate implant patients with long-term follow-up. In clinically low-risk patients, the 125 I monotherapy reportedly achieves an 87% rate of biochemical and clinical control, as demonstrated by Grimm et al. [1]. 125 I implantation offers an advantage over radical prostatectomy in that it is a less invasive out-patient procedure, has a higher rate of sexual potency preservation, and causes less acute morbidity. In terms of long-term clinical local control and freedom from biochemical failure, the results of conformal brachytherapy are as favorable as the most successful radical prostatectomy data, despite the differences in patient selection criteria. However, some comparative 5-year follow-up data indicated that PSA failure was increased for intermediate- and high-risk patients when compared with XRT, which gains an advantage in treating surrounding tissues when there is a need for their treatment [3]. Causes for Correspondence: Richard H. Matthews, M.D., Ph.D., Beth Israel/Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave., Boston, MA 02215, USA. Telephone: , ext or 5628; Fax: ; rhmatthews@comcast.net Received March 1, 2005; accepted for publication September 7, AlphaMed Press /2005/$12.00/0 The Oncologist 2005;10:

2 800 Prostate Brachytherapy Failure local failure after brachytherapy are speculative but might likely be attributed to difficulties encountered in achieving a geometrically appropriate distribution of seeds to achieve a satisfactory dose distribution within the prostate, or to inappropriate patient selection for the procedure in a monotherapy management plan [4]. Patients considered for interstitial 125 I brachytherapy are generally those classified as low risk, more specifically, those with stage T1c T2a (tumor confined to the prostate gland), PSA less than 10 ng/ml, and Gleason score of six or less. In addition, the patient should not present with any significant obstructive symptoms or perineural/extracapsular extension, the prostate volume should be less than 60 ml, and three or fewer of the six sextant biopsies should be positive. The brachytherapy approach effectively treats the prostate gland only, or perhaps a minimal margin of periprostatic tissue, and should be selected only for those patients at low risk for direct extracapsular extension of disease or microscopic seeding of the pelvic lymph nodes. Patients selected to be at low risk for extraprostatic disease treated with appropriate attention to the technical details should uncommonly experience treatment failure (a review of 400 cases treated at Massachusetts General Hospital [Boston, MA] showed only two failures; D Amico, unpublished data). Locally recurrent cancer of the prostate may lead to significant morbidity, metastasis, and death, as therapeutic options with curative intent are limited at this point. According to Grimm et al. [1], modern techniques of 125 I brachytherapy achieved an 87% rate of biochemical and clinical control in low-risk patients and 100% causespecific survival at 10 years. Johnstone notes that the question of an appropriate response to apparent local treatment failure draws variable and diverse opinions with a limited basis in evidence-based medicine [5]. In fact, PSA recurrence after treatment by radiation in general predicts for subsequent clinical failure and cause-specific death in 10 years, with the spread for biochemically controlled and biochemically failing patients depending somewhat upon the definition of biochemical failure. Classifying failure as an increase to at least 3 ng/ml PSA above the nadir leads to a spread in 10-year cause-specific death rates of 49% [6]. Here, we report the case of a patient from the minority group of implant patients who suffered PSA failure after brachytherapy treatment, discuss the salvage management offered the patient, and offer some of our thoughts on this problem area. Case Report The patient was a 64-year-old man who presented at a screening clinic on September 21, 1998, with no palpable nodule but a PSA of This led to a biopsy on December 18, 1998, yielding a Gleason score of = 6 in 5% of the tissue on the right side and 30% of the tissue on the left side of the prostate; thus, a T1c adenocarcinoma of the prostate. No persistent new bone pains were reported. He reported an International Prostate Symptom Score (IPSS) of 7/35, with mild urinary frequency and nocturia one or two times per evening. The patient also had a history of hypertension treated with amlodipine 10 mg daily and gouty arthritis treated with allopurinol 300 mg daily. The patient s brother had been diagnosed with prostate cancer and had undergone radical retropubic prostatectomy. A physical exam confirmed the absence of prostate nodularity and was otherwise unremarkable. The patient decided against radical surgery and opted for prostate 125 I brachytherapy, which appeared to be appropriate, as his PSA was less than 10, his Gleason score six or less, and his stage identified as T1c, therefore classifying him as low risk. 125 I brachytherapy was completed on April 16, 1999, delivering a peripheral dose of 144 Gy. The technique in use at the time involved a preplanning ultrasound procedure in the Radiation Therapy Department rather than an intraoperative planning procedure, and the stabilization equipment then in use may have been less ideal than equipment that would subsequently be introduced. Approximately 1 month later, the patient reported residual urinary obstructive symptoms and, in follow-up, reported an IPSS of 10/35. Terazosin 2 mg was prescribed to improve bladder function. No hematuria, incontinence, erectile dysfunction, serious diarrhea, or hematochezia was reported in immediate follow-up. From 2000 to 2002, a gradual increase in PSA ensued; doubling time appeared to be approximately 1 year. The PSA pattern was indicative of biochemical failure (American Society for Therapeutic Radiation and Oncology [ASTRO] definition). From late 2002 through April 2003, the rise in PSA accelerated and doubling time appeared to be approximately 6 months. This prompted a re-evaluation of management options. A bone scan in February 2003 was negative for metastatic disease. In April 2003 (4 years after the date of implant), a biopsy was positive for locally recurrent adenocarcinoma of the prostate. One might guess that failure was local-regional in nature with a negative metastatic work-up, but this did help confirm the presence of disease recurrent in the prostate. It also gave us some indications of the degree of aggressiveness of the cancer at this time. The patient had perineural invasion and a Gleason score of = 6 in 2/3 cores from the right side of the gland, with about 25% of tissue examined involved. An IPSS of 8/35 was reported along with moderate symptoms, including nocturia twice. Nilutamide 150 mg was administered to block the effects of testosterone at the androgen receptor level, as prostate The Oncologist

3 Kadoch, D Amico, Matthews 801 cancer usually responds to androgen ablation. At this time, pelvic radiation was considered using a moderated dose of XRT after hormonal therapy (Nilutamide) had been ongoing for approximately 2 months. The patient consented to this management option and received 4,500 cgy of XRT in 180-cGy daily fractions of 18-MV photons delivered by a shaped four-field technique to a moderate pelvic field. (Tumor dose was calculated at an isodose line encompassing the target area, the 95% isodose line being chosen. This would then make the stated dose comparable to Gy at the isocenter.) Four months after pelvic XRT combined with neoadjuvant/adjuvant hormonal therapy completed in response to the brachytherapy failure, the patient reported a 6/35 IPSS, indicated no new focal bone pains, and was otherwise unremarkable. PSA was 0.03, continuing his declining pattern (Table 1). Follow-up continuing to 2 years after completion of XRT showed the patient clinically and biochemically NED (no evidence of disease), with his last five PSA values less than He had encountered no severe complications. Discussion There is a basic importance to gaining control of prostate cancer in the local-regional area for any patient fundamentally healthy enough to receive treatment. Local persistence of disease will be expected to lead to a later wave of metastases [5 7]. The importance of local-regional disease eradication is further underscored by available dose-response data for 125 I brachytherapy implant [8], XRT [9], or pelvic XRT combined with brachytherapy as a boost [10]. Brachytherapy treats only the prostate gland effectively. If patients are selected to have a low risk of disease extension outside of the gland and treated by optimum techniques, failures will be infrequent [1]. Due to the infrequent occurrence of unfavorable outcome and undefined treatment standards, there are limited data to guide us directly when a brachytherapy failure does occur, and it will be necessary to draw inferences from several directions to arrive at a reasonable salvage treatment regimen. In addition to assessing the probability of occult distant metastasis at the time of biochemical failure (mainly PSA doubling time and restaging by physical exam, bone scan, and computed tomography), the patient s predicted survival and quality of life should be considered the major factors when deciding on a salvage treatment approach. The precise point in time at which treatment failure has occurred is an interesting question, as well as the nature or locus of the failure. Kuban et al. [11] have pointed out that the ASTRO consensus definition of failure as three successive PSA rises independent of the nadir value is based upon external-beam irradiation data only, and is strictly valid for only that management approach, although there have been attempts to extrapolate its use to brachytherapy or even radical prostatectomy. Critz [12] has argued that for a management approach in which pelvic XRT is combined with a prostate brachytherapy boost, a nadir PSA value of 0.2 or less better defines biochemically diseasefree status; according to his analysis, 99% of patients attaining this nadir level will remain disease-free after combined pelvic XRT/brachytherapy boost management. Only 16% of his patients with a nadir in the range remained disease-free. The desire to intervene quickly after the formal definition of PSA failure has been met can be tempered by some evidence that PSA rise, even with a positive local biopsy, does not inevitably lead to progressive clinical disease. Smathers and colleagues reported cases of PSA rise and positive biopsy in the first 2 years post implant followed by Table 1. PSA values associated with cancer management Date PSA (ng/ml) Comments 3/04/ /16/ I implant 5/13/ / /24/ /30/ /14/ /21/ /29/ /21/ /22/ /11/ /5/ /9/ Hormonal therapy started 6/11/ /26/03 Started pelvic XRT 7/31/03 Completed pelvic XRT 9/15/ /1/ /9/04 <0.01 7/7/04 < /10/04 <0.01 2/8/05 <0.01 8/16/05 <0.01 Abbreviations: PSA, prostate-specific antigen; XRT, external-beam radiation therapy.

4 802 Prostate Brachytherapy Failure a decline in PSA without additional treatment [13]. In the Cavanagh et al. study, it was noted that 35.8% of patients who had been judged as biochemical successes post brachytherapy had experienced an increase of 0.2 ng/ml or more, indicating that it would be best to hold off on beginning another form of therapy following observation of PSA rise of <2 3 ng/ml post brachytherapy [14]. Critz et al. [15] and Stock et al. [16] have also commented on the phenomenon of transient PSA bounce after brachytherapy as a boost with pelvic XRT or as monotherapy, respectively. Thus, observation alone may be an appropriate option in the low-risk, asymptomatic (status post [s/p] primary treatment) patient population. The morbidity and cost of secondary therapy should be carefully assessed and compared with the apparent risk of clinical progression of prostate cancer. Our issue is, then, can we identify patients who have a need for salvage treatment, and, if so, what is a reasonable form for it to take? It is evident that PSA rise is often considered a surrogate for distant metastasis and death by the cancer; more specifically, a rise in PSA of 3 ng/ml or greater is a strong indicator that clinical failure may follow PSA failure [6]. Thames and colleagues examined biochemical failure definitions for external beam irradiated patients, relative to a gold standard of clinical failure and found elevations of PSA to 2 or 3 ng/ml to be superior to the ASTRO definition of three successive rises in predicting clinical failure [17]. Our patient had encountered a rise of more than 5 ng/ml at the time salvage therapy was initiated (Table 1). In this case, the PSA doubling time appeared to be approximately 6 months and was of some concern; according to D Amico et al. [18] and others, PSA doubling time was considered to be among the best indicators of clinically significant recurrent disease, largely overriding other factors in predicting the probability of developing distant metastasis or prostate cancer death. In addition, Sartor et al. demonstrated an association between the rate of rise of PSA and clinical failure patterns; rapid rate of rise was the most significant predictor of metastatic failure. Forty-six percent of those with rapid rise (doubling time <6 months) versus 8% with moderate rate of rise (doubling time 6 months to 1 year) developed distant metastases [19]. Parker and Dearnaley have also reviewed the PSA velocity area, compiling evidence that short doubling time post XRT correlates with distant metastatic failure [20]. Patients treated by prostatectomy have risk of prostate cancer death predicted by preoperative PSA velocity [21] and progression to distant metastases predicted by PSA doubling time after postoperative PSA failure [22, 23]. Grossfeld et al. [24] studied 2,336 patients in the Cancer of the Prostate Strategic Urologic Research Endeavor treated initially with radical prostatectomy (1,744) or external-beam radiation (592). Twenty-five percent of these The Oncologist patients received secondary cancer treatment, although the type of management varied with the type of initial treatment. Patients initially treated with prostatectomy had secondary treatment consisting of XRT as salvage in 52% of cases and androgen deprivation in 47% of cases. Ninety-two percent of the failures initially treated with XRT had androgen deprivation as their secondary management. Beyer [25] in his review notes that androgen deprivation (or in some cases, only observation) generally regarded as only palliative treatment may be appropriate for recurrence after XRT due to factors such as age and comorbid diseases, or recurrence following an indolent pattern, but then makes the case that a relatively young healthy man who has what may be a local recurrence only should be considered for potentially curative salvage treatment. He suggests brachytherapy implant as a reasonable salvage treatment after PSA failure following XRT, essentially the inverse of what we are suggesting here. Grado et al. [26], in fact, used brachytherapy as a salvage approach post external-beam PSA failure, so treating a group of 49 patients (three previous implant patients and 46 XRT only) over a period of 6 years; all had biopsy-proven local recurrence. At 5 years, they report 79% cause-specific survival and 34% biochemical disease-free survival (DFS). They point out that this rate of success at salvage is comparable with what is achieved by prostatectomy salvage, but with notably fewer complications. There was only one local failure detected after salvage brachytherapy in their series, but 27 patients developed distant metastases. The implications of PSA recurrence after prostatectomy without additional treatment have been laid out in the study by Pound et al. [27]. The median time to the development of clinically evident metastases was 8 years, and the median time to death after that was 5 years. Drawing upon the literature addressing salvage XRT versus adjuvant XRT for adverse outcome s/p radical prostatectomy, we know that delayed salvage XRT, or XRT after progression to higher PSA level, is less successful in attaining DFS than adjuvant XRT early and at low PSA levels for situations such as pathological T3 disease with positive margins in the post-prostatectomy setting [28 30]. The adverse impact of a time delay could be due to seeding of the pelvic lymph nodes or the seeding of distant metastases, as to bone, in the extended time interval. If the failure involves microscopic seeding of the pelvic lymph nodes, then effective treatment of that area rather than just the prostate bed would offer a potentially curative salvage opportunity. The recently reported trial for moderately high-risk prostate cancer patients, RTOG (Radiation Therapy Oncology Group) 9413, indicated that there was an advantage in that patient population for treatment to a larger pelvic radia-

5 Kadoch, D Amico, Matthews 803 tion field rather than a smaller periprostatic tissue volume, and that there was also an advantage to combining the large pelvic field with neoadjuvant and concomitant hormonal therapy [31], rather than subsequent adjuvant hormonal therapy. There are several significant implications to this important study. First, we may reasonably hypothesize that prostate cancer frequently follows a sequential pattern of progression: first, extension out of the gland; second, investing the pelvic lymph nodes; and, third, only subsequently spreading by hematogenous metastasis to generate bone metastases. Furthermore, it suggests a synergism for neoadjuvant hormonal therapy, making 4,500 cgy to a pelvic field a worthwhile dose of radiation and one that has a reasonable prospect for eradicating a small tumor burden in the pelvis. The synergism between XRT and neoadjuvant/ adjuvant hormonal therapy is further underscored by a randomized Harvard trial of conformal radiotherapy to prostate cancer with certain risk features present (PSA at least 10, Gleason score at least 7, or radiographic evidence of extraprostatic extension) in which half the patients received XRT alone and the other half also received neoadjuvant/ adjuvant hormonal therapy [32]. The latter group enjoyed significantly superior overall survival with diminished prostate cancer related mortality. One approach that has been suggested for locally advanced or high-risk prostate cancer at the outset is to combine pelvic radiotherapy with a brachytherapy boost, with a possible advantage to combining this with hormonal therapy also [33]. Ragde et al. noted a trend in favor of using an implant boost with pelvic XRT over implant alone in reporting an implant series at a 10-year follow-up with only 6% rate of distant metastases and 2% of deaths attributed to prostate cancer [34]. The approach taken in the present case might be thought of as a reversed boost implant, albeit with a significant time delay interspersed. Critz et al. [15] have also made it a regular practice to combine a brachytherapy procedure as a boost with pelvic XRT, including patients with poorly differentiated cancers or higher PSA levels than we would usually treat with implant as monotherapy. Various other salvage treatment strategies have occasionally been used, including such possibilities as radical prostatectomy or brachytherapy reimplantation. Amling et al. reported a Mayo Clinic (Rochester, MN) experience with salvage prostatectomy following recurrence after treatment by implant or XRT; there were 108 patients so treated in 30 years [35]. Rebiopsy was used to confirm the presence of a local recurrence in all cases. The authors suggested that the procedure has resulted in long-term DFS for some patients but has not gained widespread acceptance due to the technical difficulty, and the potential for significant operative and postoperative complications. Bladder neck contracture rates were 21%, and incontinence rates were 50%. Most patients were treated with XRT, but the few treated by implant were not noted to be easy to approach surgically. This would seem a small number of patients to approach surgically over a 30-year time frame in a large surgical program; the authors estimate that only 2% 5% of previously irradiated patients are good candidates for salvage surgery. Overall survival at 10 years was 60%, and cause-specific survival was 70%. Survival free of clinical progression was 61%, and the biochemical DFS rate was 43%. Rogers et al. reported a Baylor University (Houston, TX) series of 40 salvage prostatectomies over a span of 8 years; one value of this series is that 29 of these patients had been treated by staging lymphadenectomy and brachytherapy implant, the other 11 by external-beam irradiation only [36]. They found dissection to be more difficult in the 29 patients treated by lymphadenectomy and implant than in the 11 external-beam patients. The cancer-specific survival rate was 87% at 8 years, and DFS using PSA was 33%. Pretreatment PSA more or less than 10 was prognostic in the two foregoing studies [35, 36]. Complications were worse than in primary surgery for prostate cancer, and 56% of the patients followed longer than 1 year were incontinent [36]. Schellhammer et al. also concluded that only 2% 5% of patients experiencing recurrence after treatment by radiation methods would be considered candidates for salvage surgery; furthermore, these patients are the same ones who would have the most durable response to hormonal therapy [37]. Wallner et al. reimplanted 13 patients in 10 years with generally full-dose 125 I implants; no XRT was used [38]. All 13 patients had palpable local recurrences and were then biopsy-confirmed. Freedom from local progression at 5 years was 51%, but by 6 years the rate of distant metastases had reached 100%. Two of the 13 had severe complications, and four had incontinence. Parker and Dearnaley in their review found little to recommend salvage surgery post XRT, noting difficulty of the surgical procedure, high complication rates, and poor DFS. They found little to recommend reimplantation in terms of effectiveness either [20]. Cryosurgical ablation has occasionally been used as salvage management after some type of radiotherapy failure, but in an M. D. Anderson Cancer Center (Houston, TX) study of this option, it was difficult to achieve complete ablation using salvage cryotherapy for recurrent prostate cancer (which entails freezing and completely ablating the proximal gland/tumor), and several complications occurred, such as 60% incontinence and 9% rectal fistula risks. This salvage treatment on the whole has not yielded a significant improvement in disease control [39]. A French group has recently suggested

6 804 Prostate Brachytherapy Failure a novel salvage technique, high intensity focused ultrasound, for local failures after external-beam irradiation. The 71 patients included in their series all had biopsy-confirmed local failures prior to salvage treatment. Eighty percent then had a negative biopsy post treatment, and 61% achieved a PSA nadir <0.5 ngm/ml. Median follow-up at this time is just 14.8 months, and only 44% of the patients show no evidence of disease progression [40]. Conclusion The best management of the small number of prostate brachytherapy patients encountering failure is unclear at this time. Hormonal therapy is the most commonly used secondary treatment modality but is unlikely to be curative. However, it may have value as a synergistic treatment used in a neoadjuvant/adjuvant fashion with a moderate dose of pelvic XRT, as used in RTOG 9413 [31] or the Harvard trial [32]. We attempted to use the synergism of moderate-dose pelvic XRT with neoadjuvant/adjuvant hormonal therapy and to outline what to our knowledge is an established combination treatment, but applied in a novel way as a salvage therapeutic approach that may deserve further exploration. Disclosure of Potential Conflicts of Interest The authors indicate no potential conflicts of interest. References 1 Grimm PD, Blasko JC, Sylvester JE et al. 10-year biochemical (prostatespecific antigen) control of prostate cancer with 125 I brachytherapy. Int J Radiat Oncol Biol Phys 2001;51: Beyer DC. Complications and late toxicity following definitive permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 1998;42(suppl 1): DʼAmico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280: Kollmeier MA, Stock RG, Stone N. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys 2003;57: Johnstone PAS. Biochemical failure after definitive therapy of prostate cancer: defining the chicken switch. Int J Radiat Oncol Biol Phys 2003;55: Kestin LL, Vicini FA, Martinez AA. Practical application of biochemical failure definitions: what to do and when to do it. Int J Radiat Oncol Biol Phys 2002;53: Coen JJ, Zietman AL, Thakral H et al. Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol 2002;20: Stock RG, Stone NN, Tabert A et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 1998;41: Pollack A, Zagars GK, Antolak JA et al. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized dose escalation trial. Int J Radiat Oncol Biol Phys 2002;54: Kestin LL, Goldstein NS, Vicini FA et al. Pathologic evidence of doseresponse and dose-volume relationships for prostate cancer treated with combined external beam radiotherapy and high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2002;54: Kuban DA, Thames HD, Levy LB. PSA after radiation for prostate cancer. Oncology 2004;18: Critz FA. A standard definition of disease freedom is needed for prostate cancer: undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition. J Urol 2002;167: Smathers S, Wallner K, Sprouse J et al. Temporary PSA rises and repeat prostate biopsies after brachytherapy. Int J Radiat Oncol Biol Phys 2001;50: Cavanagh W, Blasko JC, Grimm PD et al. Transient elevation of serum prostate-specific antigen following 125 I/ 103 Pd brachytherapy for localized prostate cancer. Semin Urol Oncol 2000;18: Critz FA, Williams WH, Benton JB et al. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol 2000;163: Stock RG, Stone NN, Cesaretti JA. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications. Int J Radiat Oncol Biol Phys 2003;56: Thames H, Kuban D, Levy L et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4,839 prostate cancer patients treated by external beam radiotherapy between 1986 and Int J Radiat Oncol Biol Phys 2003;57: DʼAmico AV, Cote K, Loffredo M et al. Determinants of prostate cancerspecific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002;20: Sartor CI, Strawderman MH, Lin XH et al. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys 1997;38: Parker CC, Dearnaley DP. The management of PSA failure after radical radiotherapy for localized prostate cancer. Radiother Oncol 1998;49: DʼAmico AV, Chen MH, Roehl KA et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351: Patel A, Dorey F, Franklin J et al. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 1997;158: Roberts SG, Blute ML, Bergstralh EJ et al. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 2001;76: Grossfeld GD, Li YP, Lubeck DP et al. Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor. J Urol 2002;168: The Oncologist

7 Kadoch, D Amico, Matthews Beyer DC. Salvage brachytherapy after external-beam irradiation for prostate cancer. Oncology 2004;18: Grado GL, Collins JM, Kriegshauser JS et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999;53: Pound CR, Partin AW, Eisenberger MA et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281: Crane CH, Rich TA, Read PW et al. Preirradiation PSA predicts biochemical disease-free survival in patients treated with postprostatectomy external beam irradiation. Int J Radiat Oncol Biol Phys 1997;39: Anscher MS. Salvage radiotherapy for recurrent prostate cancer. JAMA 2004;291: Stephenson AJ, Shariat SF, Zelefsky MJ et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004;291: Roach M III, DeSilvio M, Lawton C et al. Phase III trial comparing wholepelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group J Clin Oncol 2003;21: DʼAmico AV, Manola J, Loffredo M et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer. A randomized controlled trial. JAMA 2004;292: Vicini FA, Kestin LL, Stromberg JS et al. Brachytherapy boost techniques for locally advanced prostate cancer. Oncology 1999;13: Ragde H, Elgamal AA, Snow PB et al. Ten-year disease free survival after Transperineal sonography-guided Iodine-125 brachytherapy with or without 45-Gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer 1998;83: Amling CL, Lerner SE, Martin SK et al. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer. J Urol 1999;161: Rogers E, Ohori M, Kassabian VS et al. Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. J Urol 1995;153: Schellhammer PF, Kuban DA, El-Mahdi AM. Treatment of clinical local failure after radiation therapy for prostate carcinoma. J Urol 1993;150: Wallner KE, Nori D, Morse MJ et al. 125-Iodine reimplantation for locally progressive prostatic carcinoma. J Urol 1990;144: Izawa JI, Morganstern N, Chan DM et al. Incomplete glandular ablation after salvage cryotherapy for recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2003;56: Gelet A, Chapelon JY, Poissonnier L et al. Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology 2004;63: Additional Reading Principles and Practice of Radiation Oncology (Perez CA, Brady LW, Halperin EC, eds. Philadelphia: Lippincott Williams & Wilkins, 2003) Textbook of Radiation Oncology (Leibel SA, ed., Philadelphia: W.B. Saunders Co., 2004).

Salvage Brachytherapy After External-Beam Irradiation for Prostate Cancer

Salvage Brachytherapy After External-Beam Irradiation for Prostate Cancer Salvage Brachytherapy After External-Beam Irradiation for Prostate Cancer Review Article [1] February 01, 2004 By David C. Beyer, MD [2] The options available for patients with recurrent prostate cancer

More information

Outcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer

Outcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative

More information

in 32%, T2c in 16% and T3 in 2% of patients.

in 32%, T2c in 16% and T3 in 2% of patients. BJUI Gleason 7 prostate cancer treated with lowdose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure Richard G. Stock, Joshua Berkowitz, Seth R. Blacksburg and Nelson

More information

PSA is rising: What to do? After curative intended radiotherapy: More local options?

PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung

More information

Radiation Therapy for Prostate Cancer. Resident Dept of Urology General Surgery Grand Round November 24, 2008

Radiation Therapy for Prostate Cancer. Resident Dept of Urology General Surgery Grand Round November 24, 2008 Radiation Therapy for Prostate Cancer Amy Hou,, MD Resident Dept of Urology General Surgery Grand Round November 24, 2008 External Beam Radiation Advances Improving Therapy Generation of linear accelerators

More information

2/14/09. Why Discuss this topic? Managing Local Recurrences after Radiation Failure. PROSTATE CANCER Second Treatment

2/14/09. Why Discuss this topic? Managing Local Recurrences after Radiation Failure. PROSTATE CANCER Second Treatment Why Discuss this topic? Mack Roach III, MD Professor and Chair Radiation Oncology UCSF Managing Local Recurrences after Radiation Failure 1. ~15 to 75% of CaP pts recur after definitive RT. 2. Heterogeneous

More information

The Phoenix Definition of Biochemical Failure Predicts for Overall Survival in Patients With Prostate Cancer

The Phoenix Definition of Biochemical Failure Predicts for Overall Survival in Patients With Prostate Cancer 55 The Phoenix Definition of Biochemical Failure Predicts for Overall Survival in Patients With Prostate Cancer Matthew C. Abramowitz, MD 1 Tiaynu Li, MA 2 Mark K. Buyyounouski, MD 1 Eric Ross, PhD 2 Robert

More information

Over the last decade, prostate brachytherapy a radiation treatment

Over the last decade, prostate brachytherapy a radiation treatment 135 Modern Prostate Brachytherapy Prostate Specific Antigen Results in 219 Patients with up to 12 Years of Observed Follow-Up Haakon Ragde, M.D. 1 Leroy J. Korb, M.D. 1 Abdel-Aziz Elgamal, M.D. 2 Gordon

More information

Supported by M. D. Anderson Cancer Center physician investigator funds. We thank Gerald E. Hanks, MD, for help and guidance with this project.

Supported by M. D. Anderson Cancer Center physician investigator funds. We thank Gerald E. Hanks, MD, for help and guidance with this project. 1496 Biochemical and Clinical Significance of the Posttreatment Prostate-Specific Antigen Bounce for Prostate Cancer Patients Treated With External Beam Radiation Therapy Alone A Multiinstitutional Pooled

More information

New Technologies for the Radiotherapy of Prostate Cancer

New Technologies for the Radiotherapy of Prostate Cancer Prostate Cancer Meyer JL (ed): IMRT, IGRT, SBRT Advances in the Treatment Planning and Delivery of Radiotherapy. Front Radiat Ther Oncol. Basel, Karger, 27, vol. 4, pp 315 337 New Technologies for the

More information

20 Prostate Cancer Dan Ash

20 Prostate Cancer Dan Ash 20 Prostate Cancer Dan Ash 1 Introduction Prostate cancer is a disease of ageing men for which the aetiology remains unknown. The incidence rises up to 30 to 40% in men over 80. The symptoms of localised

More information

BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY

BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate

More information

PSA bouncing after brachytherapy HDR and external beam radiation therapy: a study of 121 patients with minimum 5-years follow-up

PSA bouncing after brachytherapy HDR and external beam radiation therapy: a study of 121 patients with minimum 5-years follow-up Original article Original articles PSA bouncing after brachytherapy HDR and external beam radiation therapy: a study of 121 patients with minimum 5-years follow-up Roman Makarewicz, MD, PhD, Prof., Andrzej

More information

Radiation Therapy After Radical Prostatectomy

Radiation Therapy After Radical Prostatectomy Articles ISSN 1537-744X; DOI 10.1100/tsw.2004.93 Radiation Therapy After Radical Ali M. Ziada, M.D. and E. David Crawford, M.D. Division of Urology, University of Colorado, Denver, Colorado E-mails: aziada@mednet3.camed.eun.eg

More information

Prostate Case Scenario 1

Prostate Case Scenario 1 Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has

More information

When PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy

When PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA

More information

failure (FBF) rates were calculated using the Phoenix definition.

failure (FBF) rates were calculated using the Phoenix definition. . JOURNAL COMPILATION 2009 BJU INTERNATIONAL Urological Oncology GLEASON SCORES 8 10 PROSTATE CANCER TREATED WITH TRIMODAL THERAPY STOCK et al. BJUI BJU INTERNATIONAL Outcomes for patients with high-grade

More information

Clinical Case Conference

Clinical Case Conference Clinical Case Conference Intermediate-risk prostate cancer 08/06/2014 Long Pham Clinical Case 64 yo man was found to have elevated PSA of 8.65. TRUS-biopies were negative. Surveillance PSA was 7.2 in 3

More information

Preoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy

Preoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical

More information

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1 Collecting Cancer Data: Prostate NAACCR 2010-2011 Webinar Series May 5, 2011 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview NAACCR 2010-2011 Webinar Series 1

More information

Prostate Cancer. 3DCRT vs IMRT : Hasan Murshed

Prostate Cancer. 3DCRT vs IMRT : Hasan Murshed Prostate Cancer 3DCRT vs IMRT : the second debate Hasan Murshed Take home message IMRT allows dose escalation. Preliminary data shows IMRT technique improves cancer control while keeping acceptable morbidity

More information

Treatment Failure After Primary and Salvage Therapy for Prostate Cancer

Treatment Failure After Primary and Salvage Therapy for Prostate Cancer 307 Treatment Failure After Primary and Salvage Therapy for Prostate Cancer Likelihood, Patterns of Care, and Outcomes Piyush K. Agarwal, MD 1 Natalia Sadetsky, MD, MPH 2 Badrinath R. Konety, MD, MBA 2

More information

Tanaka et al. BMC Cancer (2017) 17:573 DOI /s

Tanaka et al. BMC Cancer (2017) 17:573 DOI /s Tanaka et al. BMC Cancer (2017) 17:573 DOI 10.1186/s12885-017-3565-1 RESEARCH ARTICLE Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1

More information

A schematic of the rectal probe in contact with the prostate is show in this diagram.

A schematic of the rectal probe in contact with the prostate is show in this diagram. Hello. My name is William Osai. I am a nurse practitioner in the GU Medical Oncology Department at The University of Texas MD Anderson Cancer Center in Houston. Today s presentation is Part 2 of the Overview

More information

Prostate Cancer: 2010 Guidelines Update

Prostate Cancer: 2010 Guidelines Update Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer

More information

Subject Index. Androgen antiandrogen therapy, see Hormone ablation therapy, prostate cancer synthesis and metabolism 49

Subject Index. Androgen antiandrogen therapy, see Hormone ablation therapy, prostate cancer synthesis and metabolism 49 OOOOOOOOOOOOOOOOOOOOOOOOOOOOOO Subject Index Androgen antiandrogen therapy, see Hormone ablation therapy, synthesis and metabolism 49 Bacillus Calmette-Guérin adjunct therapy with transurethral resection

More information

External Beam Radiation Therapy for Low/Intermediate Risk Prostate Cancer

External Beam Radiation Therapy for Low/Intermediate Risk Prostate Cancer External Beam Therapy for Low/Intermediate Risk Prostate Cancer Jeff Michalski, M.D. The Carlos A. Perez Distinguished Professor of Department of and Siteman Cancer Center Learning Objectives Understand

More information

GUIDELINES ON PROSTATE CANCER

GUIDELINES ON PROSTATE CANCER 10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal

More information

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS

More information

Radiation Dose Escalation for Localized Prostate Cancer

Radiation Dose Escalation for Localized Prostate Cancer Radiation Dose Escalation for Localized Prostate Cancer Intensity-Modulated Radiotherapy Versus Permanent Transperineal Brachytherapy William W. Wong, MD 1 ; Sujay A. Vora, MD 1 ; Steven E. Schild, MD

More information

Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice

Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice european urology supplements 5 (2006) 362 368 available at www.sciencedirect.com journal homepage: www.europeanurology.com Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice Antonio

More information

How to deal with patients who fail intracavitary treatment

How to deal with patients who fail intracavitary treatment How to deal with patients who fail intracavitary treatment A. Heidenreich Department of Urology Non-surgical therapy of PCA IMRT SEEDS IGRT HDR-BRACHY HIFU CRYO LDR - Brachytherapy Author Follow-up bned

More information

Five-year outcomes after iodine-125 seed brachytherapy for low-risk prostate cancer at three cancer centres in the UK

Five-year outcomes after iodine-125 seed brachytherapy for low-risk prostate cancer at three cancer centres in the UK Five-year outcomes after iodine-125 seed brachytherapy for low-risk prostate cancer at three cancer centres in the UK Peter D. Dickinson*, Jahangeer Malik, Paula Mandall*, Ric Swindell*, David Bottomley,

More information

NIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.

NIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1. NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low

More information

EORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924

EORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924 EORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924 Title of the Study Medical Condition Androgen deprivation therapy and high dose radiotherapy with or without

More information

doi: /j.ijrobp CLINICAL INVESTIGATION

doi: /j.ijrobp CLINICAL INVESTIGATION doi:10.1016/j.ijrobp.2006.04.029 Int. J. Radiation Oncology Biol. Phys., Vol. 65, No. 4, pp. 965 974, 2006 Copyright 2006 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/06/$ see front

More information

Case Discussions: Prostate Cancer

Case Discussions: Prostate Cancer Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of

More information

Prostate Cancer in comparison to Radiotherapy alone:

Prostate Cancer in comparison to Radiotherapy alone: Prostate Cancer in comparison to Radiotherapy alone: 1 RTOG 86-10 (2001) 456 patients with > a-goserelin 2 month before RTand during RT + Cyproterone acetate (1 month) vs b-pelvic irradiation (50 gy) +

More information

HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED PROSTATE CANCER

HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED PROSTATE CANCER 0022-5347/01/1663-0876/0 THE JOURNAL OF UROLOGY Vol. 166, 876 881, September 2001 Copyright 2001 by AMERICAN UROLOGICAL ASSOCIATION, INC. Printed in U.S.A. HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED

More information

Trina Lynd, M.S. Medical Physicist Lifefirst Imaging & Oncology Cullman, AL Tri-State Alabama, Louisiana and Mississippi Spring 2016 Meeting April

Trina Lynd, M.S. Medical Physicist Lifefirst Imaging & Oncology Cullman, AL Tri-State Alabama, Louisiana and Mississippi Spring 2016 Meeting April Trina Lynd, M.S. Medical Physicist Lifefirst Imaging & Oncology Cullman, AL Tri-State Alabama, Louisiana and Mississippi Spring 2016 Meeting April 17, 2016 Discuss permanent prostate brachytherapy and

More information

Since the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors

Since the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors 2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.

More information

CLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD

CLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE II

More information

Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy

Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy Joshua J. Meeks, Marc Walker*, Melanie Bernstein, Matthew Kent and James A. Eastham Urology Service, Department of Surgery and

More information

GUIDELINEs ON PROSTATE CANCER

GUIDELINEs ON PROSTATE CANCER GUIDELINEs ON PROSTATE CANCER (Text update March 2005: an update is foreseen for publication in 2010. Readers are kindly advised to consult the 2009 full text print of the PCa guidelines for the most recent

More information

Salvage HDR Brachytherapy. Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK

Salvage HDR Brachytherapy. Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK Salvage HDR Brachytherapy Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK Disclosures Still No financial disclosures! Limited personal experience of HDR Brachy as salvage option

More information

Radiation dose has been reported to be an important determinant

Radiation dose has been reported to be an important determinant 538 The Relationship of Increasing Radiotherapy Dose to Reduced Distant Metastases and Mortality in Men with Prostate Cancer Rojymon Jacob, M.D. 1 Alexandra L. Hanlon, Ph.D. 2 Eric M. Horwitz, M.D. 1 Benjamin

More information

Advances in Treatment of Cancer by Brachytherapy in Kenya, in Particular, Prostate Cancer

Advances in Treatment of Cancer by Brachytherapy in Kenya, in Particular, Prostate Cancer Research Article imedpub Journals www.imedpub.com Journal Of Medical Physics And Applied Sciences ISSN 2574-285X DOI: 1.21767/2574-285X.12 Advances in Treatment of Cancer by Brachytherapy in Kenya, in

More information

Prostate Cancer Case Study 1. Medical Student Case-Based Learning

Prostate Cancer Case Study 1. Medical Student Case-Based Learning Prostate Cancer Case Study 1 Medical Student Case-Based Learning The Case of Mr. Powers Prostatic Nodule The effervescent Mr. Powers is found by his primary care provider to have a prostatic nodule. You

More information

Vol. 36, pp , 2008 T1-3N0M0 : T1-3. prostate-specific antigen PSA. 68 Gy National Institutes of Health 10

Vol. 36, pp , 2008 T1-3N0M0 : T1-3. prostate-specific antigen PSA. 68 Gy National Institutes of Health 10 25 Vol. 36, pp. 25 32, 2008 T1-3N0M0 : 20 2 18 T1-3 N0M0 1990 2006 16 113 59.4-70 Gy 68 Gy 24 prostate-specific antigen PSA 1.2 17.2 6.5 5 91 95 5 100 93 p 0.04 T3 PSA60 ng ml 68 Gy p 0.0008 0.03 0.04

More information

Understanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD

Understanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics

More information

Prostate brachytherapy, radical

Prostate brachytherapy, radical PSA Spike after Brachytherapy For Localized Prostate Cancer Laurie Abel Debra Zeroski Sarah Brammer Wayne Butler Kent E. Wallner Gregory S. Merrick Prostate brachytherapy, radical prostatectomy, and external

More information

When to worry, when to test?

When to worry, when to test? Focus on CME at the University of Calgary Prostate Cancer: When to worry, when to test? Bryan J. Donnelly, MSc, MCh, FRCSI, FRCSC Presented at a Canadian College of Family Practitioner s conference (October

More information

Division of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine, Durham, NC

Division of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine, Durham, NC LHRH AGONISTS: CONTEMPORARY ISSUES The Evolving Definition of Advanced Prostate Cancer Judd W. Moul, MD, FACS Division of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine,

More information

Definition Prostate cancer

Definition Prostate cancer Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation

More information

PCa Commentary. Seattle Prostate Institute CONTENTS. Volume 71 September-October 2011

PCa Commentary. Seattle Prostate Institute CONTENTS. Volume 71 September-October 2011 Volume 71 September-October 2011 PCa Commentary CONTENTS PERMANENT SEED BRACHYTHERAPY FOR HIGH- RISK PROSTATE CANCER: 1 CABOZANTINIB: Startling Responses Reported at June ASCO Meeting in Metastatic Castrate

More information

JAMA. 1998;280:

JAMA. 1998;280: Original Contributions Biochemical Outcome After Radical Prostatectomy, Radiation Therapy, or Interstitial for Clinically Localized Prostate Cancer Anthony V. D Amico, MD, PhD; Richard Whittington, MD;

More information

High-Dose Rate Temporary Prostate Brachytherapy. Original Policy Date

High-Dose Rate Temporary Prostate Brachytherapy. Original Policy Date MP 8.01.15 High-Dose Rate Temporary Prostate Brachytherapy Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature search/12/2013 Return

More information

Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series

Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,

More information

What Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen).

What Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen). What Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen). It is a very common cancer in men; some cancers grow very slowly,

More information

Monotherapy with Carbon Ion Radiation for Localized Prostate Cancer

Monotherapy with Carbon Ion Radiation for Localized Prostate Cancer Japanese Journal of Clinical Oncology Advance Access published May 30, 2006 Monotherapy with Carbon Ion Radiation for Localized Prostate Cancer Jun Shimazaki 1, Koichiro Akakura 1, Hiroyoshi Suzuki 1,

More information

S Crouzet, O Rouvière, JY Chapelon, F Mege, X martin, A Gelet

S Crouzet, O Rouvière, JY Chapelon, F Mege, X martin, A Gelet S Crouzet, O Rouvière, JY Chapelon, F Mege, X martin, A Gelet Why HIFU? Efficacy demonstrated Real time control of the target Early control of the necrosis area is possible with MRI or TRUS using contrast

More information

Information Content of Five Nomograms for Outcomes in Prostate Cancer

Information Content of Five Nomograms for Outcomes in Prostate Cancer Anatomic Pathology / NOMOGRAMS IN PROSTATE CANCER Information Content of Five Nomograms for Outcomes in Prostate Cancer Tarek A. Bismar, MD, 1 Peter Humphrey, MD, 2 and Robin T. Vollmer, MD 3 Key Words:

More information

Comparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients

Comparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients Comparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients R Kuefer 1, BG Volkmer 1, M Loeffler 1, RL Shen 2, L Kempf 3, AS Merseburger 4, JE Gschwend

More information

NICE BULLETIN Diagnosis & treatment of prostate cancer

NICE BULLETIN Diagnosis & treatment of prostate cancer Diagnosis & treatment of prostate cancer NICE provided the content for this booklet which is independent of any company or product advertised Diagnosis and treatment of prostate cancer Introduction In

More information

Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy

Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy Cagney et al. BMC Urology (2017) 17:60 DOI 10.1186/s12894-017-0250-2 RESEARCH ARTICLE Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy

More information

PROSTATE-SPECIFIC ANTIGEN (PSA) is a sensitive

PROSTATE-SPECIFIC ANTIGEN (PSA) is a sensitive Prostate-Specific Antigen Doubling Times Are Similar in Patients With Recurrence After Radical Prostatectomy or Radiotherapy: A Novel Analysis By Bryan D. Leibman, Ozdal Dillioglugil, Peter T. Scardino,

More information

Lewis Garvey Smith III, MD Reference List

Lewis Garvey Smith III, MD Reference List Journal D'Souza WD, Lee HK, Palmer MB, Smith LG, Pollack A. Is intraoperative nomogram-based overplanning of prostate implants necessary? Int J Radiat.Oncol.Biol.Phys. 56[2], 462-467. 2003 Rosser CJ, Chichakli

More information

A comparative study of radical prostatectomy and permanent seed brachytherapy for low- and intermediate-risk prostate cancer

A comparative study of radical prostatectomy and permanent seed brachytherapy for low- and intermediate-risk prostate cancer ORIGINAL RESEARCH A comparative study of radical prostatectomy and permanent seed brachytherapy for low- and intermediate-risk prostate cancer Daniel Taussky, MD; 1 Véronique Ouellet, MD; 2 Guila Delouya,

More information

When radical prostatectomy is not enough: The evolving role of postoperative

When radical prostatectomy is not enough: The evolving role of postoperative When radical prostatectomy is not enough: The evolving role of postoperative radiation therapy Dr Tom Pickles Clinical Associate Professor, UBC. Chair, Provincial Genito-Urinary Tumour Group BC Cancer

More information

Time to failure after definitive therapy for prostate cancer: implications for importance of aggressive local treatment

Time to failure after definitive therapy for prostate cancer: implications for importance of aggressive local treatment Original paper Clinical Investigations Time to failure after definitive therapy for prostate cancer: implications for importance of aggressive local treatment Al V. Taira, MD 1, Gregory S. Merrick, MD

More information

Christine M. Fisher, MD

Christine M. Fisher, MD Prostate biopsy upgrading and its implications on treatment modality and outcomes in men treated with radical prostatectomy or permanent seed implantation at UT M.D. Anderson Cancer Center, 2000-2001 By

More information

55 th Annual Meeting American Society for Radiation Oncology. Patients: Hope Guide Heal News Briefing

55 th Annual Meeting American Society for Radiation Oncology. Patients: Hope Guide Heal News Briefing 55 th Annual Meeting American Society for Radiation Oncology Patients: Hope Guide Heal News Briefing Sunday, September 22, 2013 4:45 p.m. 5:15 p.m. Colleen A.F. Lawton, MD, FASTRO 2013 ASTRO President

More information

CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM

CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM RAPID COMMUNICATION CME ARTICLE CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM ALAN W. PARTIN, LESLIE A. MANGOLD, DANA M. LAMM, PATRICK C. WALSH, JONATHAN

More information

Brachytherapy for Clinically Localized Prostate Cancer Using Permanently Implanted Seeds. Original Policy Date

Brachytherapy for Clinically Localized Prostate Cancer Using Permanently Implanted Seeds. Original Policy Date MP 8.01.11 Brachytherapy for Clinically Localized Prostate Cancer Using Permanently Implanted Seeds Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Revised

More information

Prostate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE

Prostate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE Prostate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE Low risk localised PSA < 10 ng/ml and Gleason score 6, and clinical stage T1 - T2a Intermediate risk localised PSA 10-20 ng/ml, or Gleason

More information

Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer

Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon

More information

Radiation therapy for localized prostate cancer is a main form of therapy

Radiation therapy for localized prostate cancer is a main form of therapy MANAGEMENT OF RADIATION FAILURE IN PROSTATE CANCER Selection of Salvage Cryotherapy Patients Aaron E. Katz, MD, Mohamed A. Ghafar, MD Department of Urology, College of Physicians & Surgeons of Columbia

More information

Prostatectomy as salvage therapy. Cases. Paul Cathcart - Guy s & St Thomas NHS Trust, London

Prostatectomy as salvage therapy. Cases. Paul Cathcart - Guy s & St Thomas NHS Trust, London Prostatectomy as salvage therapy Cases Paul Cathcart - Guy s & St Thomas NHS Trust, London Attributes of brachytherapy appeal to young men who place high utility on genitourinary function At risk of

More information

estimating risk of BCR and risk of aggressive recurrence after RP was assessed using the concordance index, c.

estimating risk of BCR and risk of aggressive recurrence after RP was assessed using the concordance index, c. . JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTION OF AGGRESSIVE RECURRENCE AFTER RP SCHROECK et al. BJUI BJU INTERNATIONAL Do nomograms predict aggressive recurrence after radical

More information

PET imaging of cancer metabolism is commonly performed with F18

PET imaging of cancer metabolism is commonly performed with F18 PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism

More information

Introduction ORIGINAL RESEARCH

Introduction ORIGINAL RESEARCH Cancer Medicine ORIGINAL RESEARCH Open Access Prostate- specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low- dose- rate brachytherapy

More information

Salvage low-dose-rate 125 I partial prostate brachytherapy after dose-escalated external beam radiotherapy

Salvage low-dose-rate 125 I partial prostate brachytherapy after dose-escalated external beam radiotherapy Case report Salvage low-dose-rate 125 I partial prostate brachytherapy after dose-escalated external beam radiotherapy Lynn Chang, MD 1, Mark K. Buyyounouski, MD, MS 2 Case Report 1 Department of Radiation

More information

MEDICAL POLICY. SUBJECT: BRACHYTHERAPY OR RADIOACTIVE SEED IMPLANTATION FOR PROSTATE CANCER POLICY NUMBER: CATEGORY: Technology Assessment

MEDICAL POLICY. SUBJECT: BRACHYTHERAPY OR RADIOACTIVE SEED IMPLANTATION FOR PROSTATE CANCER POLICY NUMBER: CATEGORY: Technology Assessment MEDICAL POLICY SUBJECT: BRACHYTHERAPY OR PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy

More information

Project approved by the Fondo de investigaciones Socio Sanitarias (FISS). Resolution dated June 8, Official State Gazette: June 17, 2004.

Project approved by the Fondo de investigaciones Socio Sanitarias (FISS). Resolution dated June 8, Official State Gazette: June 17, 2004. Edition No. 01 Phase III randomized and multicenter trial of adjuvant androgen deprivation combined with high-dose 3-dimensional conformal radiotherapy in intermediate- or high-risk localized prostate

More information

High Risk Localized Prostate Cancer Treatment Should Start with RT

High Risk Localized Prostate Cancer Treatment Should Start with RT High Risk Localized Prostate Cancer Treatment Should Start with RT Jason A. Efstathiou, M.D., D.Phil. Assistant Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School 10

More information

J Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION VOLUME 23 NUMBER 28 OCTOBER 1 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Predictors of Prostate Cancer Specific Mortality After Radical Prostatectomy or Radiation Therapy Ping Zhou,

More information

Prostate Cancer UK s Best Practice Pathway

Prostate Cancer UK s Best Practice Pathway Prostate Cancer UK s Best Practice Pathway TREATMENT Updated August 2018 To be updated in vember Active surveillance What is the patient s stage of disease? Low risk localised PSA < 10 ng/ml and Gleason

More information

Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer

Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group

More information

THE UROLOGY GROUP

THE UROLOGY GROUP THE UROLOGY GROUP www.urologygroupvirginia.com 1860 Town Center Drive Suite 150/160 Reston, VA 20190 703-480-0220 19415 Deerfield Avenue Suite 112 Leesburg, VA 20176 703-724-1195 224-D Cornwall Street,

More information

An Update on Radiation Therapy for Prostate Cancer

An Update on Radiation Therapy for Prostate Cancer An Update on Radiation Therapy for Prostate Cancer David C. Beyer, MD, FACR, FACRO, FASTRO Arizona Oncology Services Phoenix, Arizona Objectives Review significant new data Identify leading trends in PCa

More information

Paul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia

Paul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia Paul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia Virginia - Chesapeake Bay Landfall: Virginia Beach, April 29 th, 1607 PSA Failure after Radical Prostatectomy

More information

Prostate Cancer: Is There Standard Treatment? Who has prostate cancer? In this article:

Prostate Cancer: Is There Standard Treatment? Who has prostate cancer? In this article: Focus on CME at l Université de Montréal Prostate Cancer: Is There Standard Treatment? Pierre I. Karakiewicz, MD, FRCSC; Paul Perrotte, MD, FRCSC; Fred Saad, MD, FRCSC In this article: 1. Risk factors

More information

concordance indices were calculated for the entire model and subsequently for each risk group.

concordance indices were calculated for the entire model and subsequently for each risk group. ; 2010 Urological Oncology ACCURACY OF KATTAN NOMOGRAM KORETS ET AL. BJUI Accuracy of the Kattan nomogram across prostate cancer risk-groups Ruslan Korets, Piruz Motamedinia, Olga Yeshchina, Manisha Desai

More information

PROSTATE CANCER CONTENT CREATED BY. Learn more at

PROSTATE CANCER CONTENT CREATED BY. Learn more at PROSTATE CANCER CONTENT CREATED BY Learn more at www.health.harvard.edu TALK WITH YOUR DOCTOR Table of Contents Ask your doctor about screening and treatment options. WHAT IS PROSTATE CANCER? 4 WATCHFUL

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1

More information

2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations

2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations 2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes

More information

PSA nadir post LDR Brachytherapy and early Salvage Therapy. Dr Duncan McLaren UK & Ireland Users Group Meeting 2016

PSA nadir post LDR Brachytherapy and early Salvage Therapy. Dr Duncan McLaren UK & Ireland Users Group Meeting 2016 PSA nadir post LDR Brachytherapy and early Salvage Therapy Dr Duncan McLaren UK & Ireland Users Group Meeting 2016 Differences in PSA relapse rates based on definition used PSA ng/ml Recurrence ASTRO Recurrence

More information

Prostate Cancer Dashboard

Prostate Cancer Dashboard Process Risk Assessment Risk assessment: family history assessment of family history of prostate cancer Best Observed: 97 %1 ; Ideal Benchmark:100% measure P8 2 Process Appropriateness of Care Pre-treatment

More information

Comparative Analysis Research of Robotic Assisted Laparoscopic Prostatectomy

Comparative Analysis Research of Robotic Assisted Laparoscopic Prostatectomy Comparative Analysis Research of Robotic Assisted Laparoscopic Prostatectomy By: Jonathan Barlaan; Huy Nguyen Mentor: Julio Powsang, MD Reader: Richard Wilder, MD May 2, 211 Abstract Introduction: The

More information